Match tier Listed
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-08-08

Chinemerem M Emeasoba

Researcher

Also affiliated: Imo State University (2023); Fayetteville VA Medical Center (2025); Washington Regional Medical Center (2025); Fayetteville Public Library (2026); Northwest Medical Specialties (2026)

Faculty Researcher

1 h-index 25 pubs 7 cited

Biography and Research Information

OverviewAI-generated summary

Chinemerem M Emeasoba's research focuses on population-based health outcomes, particularly within the context of cancer and cardiovascular disease. Emeasoba has investigated the survivability of immunotherapy for colon cancer and analyzed the incidence of myocardial infarction, deep venous thrombosis, and pulmonary embolism in patients hospitalized with SARS-CoV-2. Further work examines histology-dependent survival and treatment benefits in primary tracheal cancer, as well as demographic and socioeconomic disparities in colorectal cancer screening utilization and stage at diagnosis. Emeasoba has also explored comparative outcomes of different generations of tyrosine kinase inhibitors for chronic myeloid leukemia and the prognostic impact of thromboembolic events in lung cancer patients treated with immune checkpoint inhibitors. Recent studies also involve demographic and socioeconomic disparities in access to surgery for thymic carcinoma and the development of machine learning models to predict mortality in salivary gland cancer.

Metrics

  • h-index: 1
  • Publications: 25
  • Citations: 7

Selected Publications

  • Racial Differences in Outcomes Among Patients with Multiple Myeloma Treated at a Myeloma Center of Excellence: A Retrospective Cohort Study (2026)
    Cancer Investigation DOI OpenAlex
  • Histology-dependent survival and treatment benefit in primary tracheal cancer: A population-based analysis. (2026)
    Journal of Clinical Oncology DOI OpenAlex
  • Intersectional analysis of race/ethnicity, geography, and socioeconomic status on colorectal cancer screening utilization and stage at diagnosis: A SEER analysis, 2016-2021. (2026)
    Journal of Clinical Oncology DOI OpenAlex
  • Real-world comparative outcomes of first-generation versus second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia: A global propensity-matched analysis. (2026)
    Journal of Clinical Oncology DOI OpenAlex
  • Timing and prognostic impact of thromboembolic events in lung cancer patients treated with immune checkpoint inhibitors: A time-dependent real-world analysis. (2026)
    Journal of Clinical Oncology DOI OpenAlex
  • HSR26-267: Evidence-Based Radiotherapy in Early Breast Cancer: Closing the Hypofractionation Gap (2026)
    Journal of the National Comprehensive Cancer Network DOI OpenAlex
  • HSR26-266: Navigating the Burden of Cure: Defining Survivorship Pathways in Head and Neck Cancer (2026)
    Journal of the National Comprehensive Cancer Network DOI OpenAlex
  • BPI26-006: Too Late to Test: Real-World Impact of MSI/MMR Testing Delays on Survival and Treatment in Colorectal Cancer (2026)
    Journal of the National Comprehensive Cancer Network DOI OpenAlex
  • Liver Cirrhosis and In‐Hospital Outcomes in Patients With Sickle Cell Crises (2026)
    eJHaem DOI OpenAlex
  • Real-world survival disparities and comorbidity predictors with Lu-177–PSMA-617 and PARP inhibitors in metastatic prostate cancer. (2026)
    Journal of Clinical Oncology DOI OpenAlex
  • Differential neurotoxicity patterns across neuroendocrine tumor grades: A real-world analysis of 12,847 patients. (2026)
    Journal of Clinical Oncology DOI OpenAlex
  • 495 Breaking the recurrence barrier in colon cancer: ATOMIC trial doubles disease-free survival with atezolizumab+mFOLFOX6 (2025)
    Regular and Young Investigator Award Abstracts DOI OpenAlex
  • 1073 Battle of the biologics a head to head review of CAR T cell therapy versus bispecific antibodies in B cell lymphomas balancing long term efficacy durability safety and toxicity profiles (2025)
    Regular and Young Investigator Award Abstracts DOI OpenAlex
  • 776 Melanoma tumor cells and immunotherapy cooperatively reprogram bone marrow niches to induce early hematopoietic dysfunction and therapy-related myeloid neoplasms (2025)
    Regular and Young Investigator Award Abstracts DOI OpenAlex
  • 426 Reprogramming tumor metabolism to overcome immune evasion: GLUT1 blockade synergizes with PD1/CTLA-4 therapy in non-small cell lung cancer (2025)
    Regular and Young Investigator Award Abstracts DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

41 Collaborators 17 Institutions 2 Countries

Top Collaborators

View profile →

Similar Researchers

Based on overlapping research topics